All News
How are RA patients doing using telemedicine/virtual care?
Rheumatologists switched their practices overnight from primarily in person to nearly all virtual care as COVID-19 pandemic geared up in March 2020 and then to a blend of in person and virtual care. How are RA patients doing?
Read Article
Racial disparities in Bilateral Knee Arthroplasty in Osteoarthritis
Although arthritis-related activity, disabling work limitations, and severe pain (which are indications for TKA) disproportionately impact African American patients compared to White patients, there are marked racial disparities documented in utilization and complications in unilateral total knee arthroplasty.
Read Article
Revisit #ACR20 with our RheumNow podcast.
https://t.co/ondNw0G6Pu https://t.co/nauqdGp8fR
Links:
Dr. John Cush RheumNow ( View Tweet)
Worth the read!
My Experience as a COVID19 Vaccine Trial Participant by Dr. Kathryn Dao ( @KDAO2011)
https://t.co/ILfXLUL8IZ https://t.co/7parTGPllu
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @MeralElRamahiMD : Switching or adding a DMARD in pts w/ mod-high dz RA activity ; hx of previous serious infection w/in the past 12 mos as opposed to starting/increasing GCs is conditionally recommended per draft recs of new ACR RA treatment guidelines.
Dr. John Cush RheumNow ( View Tweet)
Prothrombotic Antiphospholipid Antibodies in COVID-19: Dr. David Liew ( @drdavidliew) abstract #0429 at the #ACR20.
https://t.co/5xjThWuLa6 https://t.co/Aezlfqle06
Links:
Dr. John Cush RheumNow ( View Tweet)
New Treatments in Axial Spondyloarthritis: Dr. Antoni Chan ( @synovialjoints) discuses two abstracts presented at the #ACR20 annual meeting.
https://t.co/bh7l6C8p7P https://t.co/RN60iWCmet
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @RichardPAConway :Dr Cid presents phase 2 trial of anti-GM-CSF agent mavrilimumab in combination with steroids in GCA. 70 patients. Sustained remission at week 26 in 83.2% of mavrilimumab vs 49.9% of placebo p=0.0038. @DrPujaMehta1 #ACR20 Abstr#L06 https://t.co/ynWbguXXzR
Dr. John Cush RheumNow ( View Tweet)
IVIg in Dermatomyositis: Dr. Sheila Reyes ( @RHEUMarampa) reviews abstract #0995 presented at #ACR20.
https://t.co/PKYATqUh0d
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @KDAO2011 : Very strong push by #ACR20 to recc MTX in most RA patient scenarios including RA ILD, RA nodules, NAFLD in new RA guidance document @rheumnow
Dr. John Cush RheumNow ( View Tweet)
Citrulline Reactive B Cells Present in Lungs of Risk, Early RA: Richard Conway ( @RichardPAConway) discusses ACR abstract #1445 presented #ACR20
https://t.co/WjcBPay86P https://t.co/JnUVss0FDK
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @DrMiniDey : Patient-physician discordance seen in ~30% RA patients starting #DMARDs
- ↑Patient-reported pain; functional impairment assoc. w/ discordance
- Patient-centric treatment discussions needed to reduce discordance
Abs#1978
https://t.co/uTJehn5Qs5 https://t.co/289d3VsE22
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @doctorRBC : Upadacitinib vs. Adalimumab vs. PBO in PsA
Phase 3 RCT
⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA
*⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior
*⃣Similar VTE in all arms
#ACR20 Abs#2026 https://t.co/n5wcKK1juC
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : Does IL-6 blockade prevent mechanical ventilation or death in #COVID19? MGH study by Dr. Stone Abst#L07 graph shows no benefit #ACR20 https://t.co/JWa1LSIC8R https://t.co/EOEoHhmKqk
Dr. John Cush RheumNow ( View Tweet)
RA Risk Factors and Early RA: Dr. Jeffrey Sparks ( @jeffsparks) and Dr. Janet Pope ( @Janetbirdope) #ACR20
https://t.co/vN7Dt60R4W https://t.co/K5vAhEQfks
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Kay leads an internat'l panel of rheums to elicit their opinions on key abstracts at #ACR20.
Panelists: Dr. David Liew, Dr. Eric Dein, Dr. Meral El Ramahi, Dr. Richard Conway, Dr. Sheila Reyes and Dr. Jeffrey Sparks.
https://t.co/Jg6QiswnnJ https://t.co/UAqiN3F734
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
FAST trial (Plenary) showed opposite of CAREs study. Febuxostat vs PBO in 6128 Gout pts, showed little dropout (~6%) in a 4 year study. Febuxostat (mean 81mg) had similar, flare rates, MACE/cardiac endpoints and CV death vs allopurinol #ACR20 Abstr#L08 https://t.co/EUXQqy3VuI
Dr. John Cush RheumNow ( View Tweet)
Timely video on COVID 19 and Rheumatic Disease with Dr. Jeffrey Sparks ( @jeffsparks) #acr20
https://t.co/5Qg3HRkQyW
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @RichardPAConway :Dr MacDonald presents Febuxostat versus Allopurinol Streamlined Trial. 6128 patients. HR 0·89 [95% CI 0·75-1·06] for cardiovas. events in febuxostat vs allopurinol. Mortality 7.2% vs 8.6%. Reassuring re cardiovascular safety of febuxostat
Dr. John Cush RheumNow ( View Tweet)
Dr. Rachel Tate ( @uptoTate) reviews outpatient billing and coding pearls presented at a session at the #ACR20 meeting.
https://t.co/66YbqXcncr https://t.co/PDdVKfNJYd
Links:
Dr. John Cush RheumNow ( View Tweet)